Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » By Affiliations
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Prostate-specific antigen in breast disease

Poh, Bee Hoon, and Jayaram, G., and Sthaneshwar, Pavai, and Yip, Cheng Har, (2008) Prostate-specific antigen in breast disease. Malaysian Journal of Pathology, 30 (1). pp. 43-51. ISSN 0126-8635

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
345Kb

Official URL: http://www.mjpath.org.my/2008.1/07_Prostate-specific_antigen_in_breast_disease.pdf

Affiliations

University of Malaya Medical Centre. Dept. of Pathology
University of Malaya Medical Centre. Dept. of Pathology
University of Malaya Medical Centre. Dept. of Pathology
University of Malaya Medical Centre. Dept. of Surgery

Abstract

The aim of this study is to assess tissue and serum prostate-specific antigen (PSA) in breast lesions; to compare tissue PSA with serum PSA; to compare tissue PSA in benign and malignant lesions and to compare PSA with known prognostic factors in breast carcinoma. Tissue PSA immunoreactivity in twenty women with breast carcinoma was compared with PSA in twenty-three women with benign breast lesions. Tissue PSA was also compared with known prognostic indicators such as tumour size, axillary nodal status, histological type, histological grade, oestrogen receptor status, progesterone receptor status and c-erbB-2 oncoprotein over-expression. Serum free PSA levels from these women were measured pre- and post-operatively and an attempt was made to correlate serum PSA with tissue PSA expression. 40% and 43% of malignant and benign breast lesions respectively showed tissue PSA immunoreactivity. No significant difference was observed in the tissue PSA expression between these two groups as also between tissue PSA and known prognostic indicators. As serum PSA levels were below the detection limit (< 0.004 ng/ml) in all except two benign cases, no statistical evaluation was done for the latter. Tissue PSA expression did not correlate with other prognostic markers and detectable serum PSA levels were present in too few cases for statistical analysis. Although no definitive conclusion is possible in this preliminary study regarding the role of PSA in breast disease, it stimulates interest in further research in this direction.

Item Type:Journal
Additional Information:The work was supported by Vote F 0395/2003B of University of Malaya. We would like to thank Dr. K. F. Quek for assistance and input in the statistical analysis of the clinical data. This study was reviewed and approved by the Medical Ethics Committee of the University Malaya Medical Centre.
Keywords:Tissue prostate-specific antigen, serum prostate-specific antigen, breast neoplasms.
Subjects:R Medicine, Dentistry, Pharmacy, Nursing
ID Code:6289

1. Armbruster DA. Prostate specific antigen: biochemistry, analytical methods and clinical application. Clin Chem 1993; 39: 181-95.

2. el-Shirbiny AM. Prostate specific antigen. Adv Clin Chem 1994; 31: 99-133.

3. Lilja H. Structure, function and regulation of the enzyme activity of prostate specific antigen. World J Uro 1993; 11: 188-91.

4. Clements JA, Mukhtar A, Verity K, Pullar M, Mcneill P, Cummis H, et al. Kallikrein gene expression in human pituitary tissue. Clin Endocrinol 1996;44:223-31.

5. Mannello F, Sebastian M, Amati S, Gazzanelli G. Prostate-specific antigen expression in a case of intracystic carcinoma of the breast: characterization of immunoreactive protein and literature surveys. Clin Chem 1997; 43: 1448-54.

6. Melegos DN, Freedman MS, Diamandis EP. Prostate-specific antigen in cerebrospinal fluid. Clin Chem 1997; 43:855.

7. Levesque M, Yu H, D’Costa M, Diamandis EP. Prostate-specific antigen expression by various tumours. J Clin Lab Anal 1995; 9: 123-8.

8. Howarth DJC, Aronson IB, Diamandis EP. Immunohistochemical localization of prostatespecific antigen in benign and malignant breast tissues. Br J Cancer 1997; 75: 1646-51.

9. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40:171-8.

10. Diamandis EP, Yu H, Sutherland DJA. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:301-10.

11. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age.Clin Biochem 1994; 27: 75-9.

12. Alanen KA, Kuopio T, Collan YU, Kronqvist P, Juntti L, Nevalainen TJ. Immunohistochemical labeling of prostate-specific antigen in breast carcinomas. Breast Cancer Res Treat 1999; 56:169-76.

13. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998 4: 1489-97.

14. Yu H, Levesque MA, Clark GM, Diamandis EP. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br J Cancer 1999; 81: 490-5.

15. Yu H, Giai M, Diamandis EP, et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995; 55:2104-10.

16. Black MH, Diamandis EP. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 2000; 59:1-14.

17. Lehrer S, Terk M, Piccoli SP, et al. Reverse transcriptase-polymerase chain reaction for prostatespecific antigen may be a prognostic indicator in breast cancer. Br J Cancer 1996; 74:871-3.

18. Melegos DN, Diamandis EP. Is prostatic-specific antigen present in female serum? Clin Chem 1998; 44: 691-2.

19. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, et al. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 1995; 72: 728-31.

20. Borchert GH, Melagos DN, Tomlinson G, et al. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast disease. Br J Cancer 1997; 76:1087-94.

21. Zarghami N, Grass L, Sauter ER, Diamandis EP. Prostate-specific antigen in serum during the menstrual cycle. Clin. Chem 1997; 43:1862-7.

22. Black MH, Giai M, Ponzone R, Sismondi P, Yu H, Diamandis EP. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res 2000; 6: 467-73.

23. Huland E, Haese A, Huland H. Supersensitive detection of prostate-specific antigen in lyophilisation-concentrated serum: a rapid and simple procedure. Int J Oncol 1996; 9: 593-601.

24. Diamandis EP, Yu H, Lopez-Otin C. Prostate-specific antigen – a new constituent of breast cyst fluid. Breast Cancer Res Treat 1996; 38:259-64.

25. Dibbelt L, Vierke G, Wunsche W. Prostate-specific antigen immunoreactivity in women with breast cancer. Clin Chem 1996 42: 1721-2.

26. Forbes JF. The incidence of breast cancer: the global burden, public health considerations. Sem Oncol 1997; 24: S120-S135.

27. Hisham NA, Yip CH. Spectrum of breast cancer in Malaysian women: Overview. World J Surg 2003;27: 921-3.

28. Yip CH, Ng EH. Breast Cancer; a comparative study between Malaysian and Singaporean women. Singapore Med J 1996; 37: 264-7.

29. Foekens JA, Diamandis EP, Yu H, Look MP, Meijervan Gelder ME, van Putten WLJ, et al. Expression of prostate-specific antigen correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 1999; 79: 888-94.

30. Heyl W, Wolff JM, Biesterfeld S, Schroder W, Zitselsberger D, Jakse G, et al. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer. Anticancer Res 1999; 19: 2563-6.

31. Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen in human breast carcinoma cells. Anticancer Res 1997; 17:2577-82.

32. Griniatsos J, Diamandis EP, Gioti J, Karyda I, Vassilopoulos PP, Agnanti N. Correlation of prostate-specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer. Anticancer Res 1998; 18: 683-8.

33. Bradshaw HL, Fleishre M, Breed CN, Chasalow FI. Biochemical classification of patients with gross cystic breast disease. Ann NY Acad Sci 1990;586:12-6.

34. Mannello F, Bocchiotti G, Bianchi G, Marcheggiani F, Gazzanelli G. Quantitation of prostate-specific antigen immunoreactivity in human breast cyst fluids. Breast Cancer Res Treat 1996; 38: 247-52.

35. Yu H, Diamandis EP, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 1994; 32:291-300.

36. Yu H, Diamandis EP, Monne M, Croce CM. Oral contraceptive-induced expression of prostatespecific antigen in the female breast. J Biol Chem 1995; 270: 6615-8.

37. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumour cell lines by insulingrowth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994; 54:5474-8.

38. Breul J, Pickl U, Schaff J. Extraprostatic production of prostate specific antigen is under hormonal control. J Uro 1997; 157: 212-3.

39. Diamandis EP, Yu H. Editorial: New biological functions of prostate specific antigen. J Clin Endocrinol Metab 1995; 80: 1515-7.

40. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite®

immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996; 42: 675-84.

41. Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Ultrasensitive detection of prostate specific antigen in the follow-up of 422 patients after radical prostatectomy. J Urol 1999;161: 1206-11.

42. Hautmann S, Huland E, Grupp C, Haese A, Huland H. Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer. Anticancer Res 2000; 20: 2151-4.

43. Mannello F, Gazzanelli G. Prostate specific antigen PSA/hK3): a further player in the field of breast cancer diagnostics? Breast Cancer Res 2001; 3:238-43.

44. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumours. Cancer Res 1994; 54: 6344-7.

45. Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rat and humans: A unifying hypothesis. Proc Natl Acad Sci USA 1995; 92: 3650-7.

46. Parish DC. Prostate specific antigen in the breast. Endo-Rel Cancer 1998; 5: 223-9.

47. Pruthi RS, Haese A, Huland E, Stamey TA. Use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy. Urology 1997; 49: 404-10.

48. Romppanen J, Keskikuru R, Kataja V, Eskelinen N, Kosma VM, Savolainen K, et al. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer 1999; 79:1583-7.

49. Ulutin HC, Park Y. Prostate specific antigen in the female body: its role in breast cancer prognosis. Radiat Med 2000; 18: 273-6.

Repository Staff Only: item control page
 
 
 
 
 
   
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.